ZB
MRNA icon

Zions Bancorporation’s Moderna MRNA Stock Holding History

Zions Bancorporation’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$2.21K – 879
2024
Q3 		$2.21K Sell
33
-111
-77% -$10.2K ﹤0.01% 785
2024
Q2 		$17.1K Sell
144
-9
-6% -$1.14K ﹤0.01% 578
2024
Q1 		$16.3K Buy
153
+51
+50% +$5.14K ﹤0.01% 584
2023
Q4 		$10.1K Sell
102
-107
-51% -$9K ﹤0.01% 655
2023
Q3 		$21.6K Sell
209
-1
-0.5% -$112 ﹤0.01% 502
2023
Q2 		$25.5K Sell
210
-29
-12% -$3.87K ﹤0.01% 490
2023
Q1 		$36.7K Sell
239
-41
-15% -$6.76K ﹤0.01% 453
2022
Q4 		$50.3K Buy
280
+69
+33% +$11.3K ﹤0.01% 445
2022
Q3 		$25K Buy
211
+11
+6% +$1.67K ﹤0.01% 515
2022
Q2 		$29K Sell
200
-75
-27% -$10.7K ﹤0.01% 539
2022
Q1 		$47K Buy
275
+14
+5% +$2.36K ﹤0.01% 519
2021
Q4 		$66K Buy
261
+55
+27% +$16.1K 0.01% 424
2021
Q3 		$79K Buy
206
+48
+30% +$17.7K 0.01% 403
2021
Q2 		$37K Buy
158
+16
+11% +$2.86K ﹤0.01% 461
2021
Q1 		$19K Sell
142
-38
-21% -$5.51K ﹤0.01% 578
2020
Q4 		$19K Buy
180
+84
+88% +$8.5K ﹤0.01% 554
2020
Q3 		$7K Buy
96
+28
+41% +$1.95K ﹤0.01% 756
2020
Q2 		$4K Buy
+68
New +$3.72K ﹤0.01% 780

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Zions Bancorporation's MRNA Position: Q4 2024 in Review

Zions Bancorporation sold out of Moderna (MRNA) in Q4 2024, closing a stake of 33 shares — an estimated $2.21K sold.

Zions Bancorporation first reported a position in MRNA in Q2 2020 and held it in 18 quarters. The position peaked at $79K in Q3 2021. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Zions Bancorporation reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Zions Bancorporation sold 33 Moderna shares in Q4 2024, an estimated $2.21K.
  • Zions Bancorporation first reported a position in Moderna in Q2 2020 and held it in 18 quarters.
  • Zions Bancorporation's Moderna position peaked at $79K in Q3 2021.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.